Company Overview

MAIA Biotechnology, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of targeted immunotherapies for cancer. The company operates within the oncology and biopharmaceutical industries, with a strategic emphasis on therapies designed to exploit cancer cell immortality mechanisms linked to telomere biology. MAIA’s lead product candidate is telomere-targeting agent THIO (6-thio-2’-deoxyguanosine), which is being developed primarily for advanced non-small cell lung cancer and other solid tumors. The company’s business model centers on clinical development, intellectual property generation, regulatory advancement, and potential future commercialization or partnering opportunities for oncology therapeutics.

MAIA was founded in 2018 and is headquartered in Chicago, Illinois. Since inception, the company has concentrated on advancing telomere-directed therapies intended to selectively affect telomerase-positive cancer cells while activating anti-tumor immune responses. MAIA became publicly traded on the NYSE American exchange under the ticker “MAIA.” Its positioning in the oncology market is differentiated by its focus on telomere dysfunction and immune activation as a combined therapeutic strategy, an area that remains relatively specialized compared with broader immuno-oncology and targeted therapy markets.

Business Operations

MAIA’s operations are centered primarily around its oncology drug development platform and related clinical research activities. The company does not currently generate commercial product revenue and instead operates as a clinical-stage biotechnology enterprise funded through equity financing, public market activity, and strategic capital raising initiatives. Its core operational focus is the advancement of THIO, including clinical trials, regulatory engagement, manufacturing coordination, and translational research. MAIA has evaluated THIO both as a monotherapy and in combination with immune checkpoint inhibitors to enhance anti-cancer immune responses.

The company’s operational footprint includes research collaborations, clinical trial partnerships, and outsourced manufacturing and development relationships across the United States and internationally. MAIA relies on contract research organizations, clinical investigators, and manufacturing partners to support development activities rather than maintaining large-scale internal manufacturing infrastructure. The company also controls intellectual property related to telomere-targeting technologies and therapeutic applications involving telomerase-positive cancers. Public filings indicate that MAIA has pursued collaborations with academic institutions and oncology research centers to support clinical development and scientific validation efforts.

Strategic Position & Investments

MAIA’s strategic direction is focused on expanding the clinical utility of telomere-targeting therapies in oncology and positioning THIO as a potentially differentiated treatment option for difficult-to-treat cancers. The company has emphasized combination treatment strategies involving checkpoint inhibitors and immune-mediated therapeutic approaches. Clinical development efforts have included studies in advanced non-small cell lung cancer, particularly in patient populations with limited treatment alternatives following standard therapies.

The company’s investments have primarily been directed toward clinical trials, intellectual property protection, regulatory advancement, and scientific research supporting telomere biology applications in cancer treatment. MAIA has also explored broader opportunities involving immune activation mechanisms associated with telomere disruption. Publicly available information identifies THIO as the company’s principal asset and strategic focus. Data inconclusive based on available public sources regarding material wholly owned operating subsidiaries or large-scale acquisition activity comparable to larger biotechnology companies.

Geographic Footprint

MAIA Biotechnology is headquartered in Chicago, Illinois, United States, and its operational activities are concentrated primarily in North America and selected international clinical research markets. The company’s clinical trial activities have involved multiple research centers and oncology institutions, including sites outside the United States as part of broader development and regulatory strategies.

While MAIA does not currently maintain the extensive global commercial infrastructure typical of large pharmaceutical companies, it has pursued international clinical engagement and scientific collaboration in support of oncology development programs. Its market focus remains largely tied to regions with established oncology drug development ecosystems, including the United States and parts of Europe. The company’s broader international influence is currently driven more by clinical and scientific partnerships than by commercial sales operations.

Leadership & Governance

MAIA Biotechnology’s leadership team is composed of biotechnology, pharmaceutical, finance, and oncology industry executives focused on advancing the company’s clinical-stage oncology pipeline. The company’s governance structure reflects a typical publicly traded biotechnology model emphasizing clinical execution, capital management, scientific oversight, and regulatory advancement. Leadership communications and public filings consistently emphasize innovation in telomere biology, disciplined clinical development, and the pursuit of differentiated cancer therapies.

Key executives and leadership figures include:

• Vlad Vitoc, M.D. – Chief Executive Officer and Chairman
• Andrew Gengos – President and Chief Financial Officer
• Lawrence Diamond, Ph.D. – Chief Medical Officer
• Aytac Yucel, Ph.D. – Chief Development Officer

The company’s strategic vision has centered on developing targeted therapies that leverage telomere dysfunction and immune activation mechanisms to improve outcomes in oncology indications with unmet medical needs. Public disclosures, including SEC filings, investor materials, and corporate communications, consistently identify clinical advancement of THIO as the organization’s primary operational objective.